Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | May 01, 2026 | May 01, 2026 |
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 19, 2022 | May 23, 2022 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 11, 2023 | August 15, 2023 |
| LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447 | Director | June 04, 2022 | June 07, 2022 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | January 06, 2026 | January 08, 2026 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | May 12, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.82 · Expires 2036-05-01 | Direct | 48,800 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 48,800 · Balance 48,800 F1: The options were granted pursuant to the Company's non-employee director compensation policy. F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the Company's non-employee director compensation policy.
F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.
Axcella Health Inc.
Report date May 19, 2022 · Filed May 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2032-05-18 | Direct | 20,000 |
Reported balance
After 2022-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-19 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.
Jazz Pharmaceuticals plc
Report date August 11, 2023 · Filed August 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 14,868 |
Ending reported balance
After 2023-08-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-08-11 · Grant · Acquired 3,075 · Balance 16,109 F1: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Row 2 · 2023-08-14 · Sale · Disposed 1,241 · Balance 14,868 F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.78 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024.
F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.78 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
LIFECORE BIOMEDICAL, INC. \DE\
Report date June 04, 2022 · Filed June 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,069 |
Reported balance
After 2022-06-04 transaction · row 1
1 source rowRow 1 · 2022-06-04 · Grant · Acquired 7,059 · Balance 54,069 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2022-06-04 | Direct | 0 |
Reported balance
After 2022-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-04 · Exercise / conversion · Disposed 7,059 · Balance 0 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: The restricted stock units were granted on June 4, 2021. F3: The restricted stock units vested on June 4, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
F2: The restricted stock units were granted on June 4, 2021.
F3: The restricted stock units vested on June 4, 2022.
Maze Therapeutics, Inc.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-01-07 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-01-06 · Exercise / conversion · Acquired 2,493 · Balance 2,493 Row 2 · 2026-01-06 · Sale · Disposed 2,493 · Balance 0 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4. Row 3 · 2026-01-07 · Exercise / conversion · Acquired 20,744 · Balance 20,744 Row 4 · 2026-01-07 · Exercise / conversion · Acquired 2,895 · Balance 23,639 Row 5 · 2026-01-07 · Exercise / conversion · Acquired 3,281 · Balance 26,920 Row 6 · 2026-01-07 · Sale · Disposed 26,920 · Balance 0 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2033-03-08 | Direct | 3,211 |
Reported balance
After 2026-01-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-06 · Exercise / conversion · Disposed 2,493 · Balance 3,211 F3: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-07 · Exercise / conversion · Disposed 20,744 · Balance 0 F4: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2033-03-08 | Direct | 316 |
Reported balance
After 2026-01-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-07 · Exercise / conversion · Disposed 2,895 · Balance 316 F3: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2034-12-08 | Direct | 5,805 |
Reported balance
After 2026-01-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-01-07 · Exercise / conversion · Disposed 3,281 · Balance 5,805 F5: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive.
F3: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F4: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024.
F5: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Rubius Therapeutics, Inc.
Report date May 12, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11 | Direct | 25,000 |
Reported balance
After 2022-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2020 Filed May 22, 2020 21:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001104659-20-065473 · a4.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-05-19 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:38 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 1,000 | $4.87 | $4,870.00 |
DisclosureSEC source: 0001633070-20-000002 · wf-form4_157964267039151.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 19:16 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantRight to Buy Restricted Stock Unit (RSU) · Derivative | 2,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-19-012373 · wf-form4_157133976524642.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 2,200 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 21:29 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock · Derivative | 10,000 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001628280-19-012187 · wf-form4_157048374467434.xml · derivative · entry 3 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 21:29 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Tax withholdingCommon Stock | 8,824 | $10.21 | $90,093.04 |
DisclosureSEC source: 0001628280-19-012187 · wf-form4_157048374467434.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,507 Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 21:29 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 10,000 | $9.01 | $90,100.00 |
DisclosureSEC source: 0001628280-19-012187 · wf-form4_157048374467434.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 20:34 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001104659-19-047155 · a4.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-21 F1 · derivative.exercise_date: This option shall vest in equal 1/12th quarterly installments during the twelve quarters following the grant date and become fully exercisable on the third anniversary of the grant date. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 726 | $135.65 | $98,482.12 |
DisclosureSEC source: 0001765581-19-000078 · edgardoc.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,848 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.65 to $135.7054. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,805 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001765581-19-000078 · edgardoc.xml · derivative · entry 3 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Common Stock · 4,805 shares Expires 2029-08-07 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000078 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,574 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020. Read SEC document |
| May 30, 2019 Filed May 31, 2019 00:39 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 4,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-007414 · wf-form4_155926316005918.xml · derivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,240 shares Expires 2019-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on May 30, 2018. F3 · derivative.exercise_date: The restricted stock units vested on May 30, 2019. F3 · derivative.expiration_date: The restricted stock units vested on May 30, 2019. Read SEC document |
| May 30, 2019 Filed May 31, 2019 00:39 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 4,240 | $9.91 | $42,018.40 |
DisclosureSEC source: 0001628280-19-007414 · wf-form4_155926316005918.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document |
| May 28, 2019 Filed May 31, 2019 00:39 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | GrantRight to Buy Restricted Stock Units (RSU) · Derivative | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-19-007414 · wf-form4_155926316005918.xml · derivative · entry 3 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F4 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| May 23, 2019 Filed May 28, 2019 19:59 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001104659-19-032122 · a4.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 20:44 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | PurchaseCommon Stock | 1,000 | $11.23 | $11,230.00 |
DisclosureSEC source: 0001437749-19-000726 · rdgdoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,091 Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 22:20 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 660 | $176.61 | $116,563.13 |
DisclosureSEC source: 0001232524-18-000140 · edgardoc.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,654 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.61 to $177.1295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:20 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,735 | $0.00 Strike: $177.73 | $0.00 |
DisclosureSEC source: 0001232524-18-000140 · edgardoc.xml · derivative · entry 3 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,735 Underlying: Ordinary Shares · 3,735 shares Expires 2028-08-08 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:20 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000140 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,314 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | PurchaseCommon Stock | 2,500 | $23.00 | $57,500.00 |
DisclosureSEC source: 0001104659-18-046532 · a4.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| July 17, 2018 Filed Jul 18, 2018 16:33 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001104659-18-045774 · a4.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: This option shall vest in equal quarterly installments during the twelve quarters following the grant date. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:35 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 4,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-011098 · rdgdoc.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,240 Underlying: Common Stock · 4,240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| May 23, 2018 Filed May 25, 2018 21:38 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 4,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-010771 · rdgdoc.xml · derivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,286 shares Expires 2018-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on June 1, 2017. F3 · derivative.exercise_date: The restricted stock units vested on May 23, 2018. Read SEC document |
| May 23, 2018 Filed May 25, 2018 21:38 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 4,286 | $13.65 | $58,503.90 |
DisclosureSEC source: 0001437749-18-010771 · rdgdoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3 | $144.22 | $432.65 |
DisclosureSEC source: 0001232524-17-000152 · edgardoc.xml · nonDerivative · entry 3 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,819 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 659 | $142.36 | $93,815.24 |
DisclosureSEC source: 0001232524-17-000152 · edgardoc.xml · nonDerivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,822 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,415 | $0.00 Strike: $143.66 | $0.00 |
DisclosureSEC source: 0001232524-17-000152 · edgardoc.xml · derivative · entry 4 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,415 Underlying: Ordinary Shares · 3,415 shares Expires 2027-08-09 F3 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000152 · edgardoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,481 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. F1 · shares: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 23:26 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 4,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-17-010672 · rdgdoc.xml · derivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,286 Underlying: Common Stock · 4,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| May 25, 2017 Filed May 26, 2017 23:05 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 5,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-010193 · rdgdoc.xml · derivative · entry 2 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,282 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on May 25, 2016. F3 · derivative.exercise_date: The restricted stock units vested on May 25, 2017. F3 · derivative.expiration_date: The restricted stock units vested on May 25, 2017. Read SEC document |
| May 25, 2017 Filed May 26, 2017 23:05 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 5,282 | $13.50 | $71,307.00 |
DisclosureSEC source: 0001437749-17-010193 · rdgdoc.xml · nonDerivative · entry 1 Sohn Catherine A. · CIK 0001555132 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.